

# PRECEPTORSHIP PROGRAMME

## Lung Cancer and other Thoracic Malignancies

**ESMO  
PRECEPTORSHIP**

**PARIS FRANCE  
17-18 NOVEMBER 2022**

New standards of care and future perspectives.

**Chairs:**

Fabrice Barlesi, France  
Solange Peters, Switzerland  
David Planchard, France

# ESMO PRECEPTORSHIP PROGRAMME

## LUNG CANCER AND OTHER THORACIC MALIGNANCIES

New standards of care and future perspectives

Paris, France  
17-18 November 2022

---

**CO-CHAIRS:** Fabrice Barlesi, France  
Solange Peters, Switzerland  
David Planchard, France

**SPEAKERS:** Benjamin Besse, France  
Corinne Faivre-Finn, United Kingdom  
Marina Garassino, United States  
Lizza Hendriks, Netherlands  
Keith M. Kerr, United Kingdom  
Cécile Le Pechoux, France  
Tony S.K. Mok, Hong Kong  
Antonio Passaro, Italy  
Sanjay Popat, United Kingdom  
Jordi Remon, France

---

### LEARNING OBJECTIVES

- To learn about best clinical practice in the management of NSCLC in early, locally advanced, and metastatic stages
- To learn about the management of patients with actionable driver alterations and novel targeted agents for advanced NSCLC
- To understand the role of immune checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about the systemic treatment of mesothelioma, SCLC and thymoma

---

### ACCREDITATION

The programme of this event has been accredited with 11 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update his/her knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details please refer to [esmo.org](http://esmo.org).

---

### ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



---

### ORGANISATION AND CONTACTS

ESMO Head Office  
Education Department  
Via Ginevra 4  
6900 Lugano  
Switzerland  
Email: [courses@esmo.org](mailto:courses@esmo.org)  
[www.esmo.org](http://www.esmo.org)



## Thursday, 17 November 2022

<b>09:00-09:10</b> 10'	<b>Welcome and introduction</b>	<b>Solange Peters, CH</b> <b>David Planchard, FR</b>
<b>09:10-11:10</b> 120'	<b>SESSION 1</b> <b>Multimodality treatment in early stage</b>	<b>Chairs: Fabrice Barlesi, FR</b> <b>Antonio Passaro, IT</b>
25'	Adjuvant RT for completely resected early-stage NSCLC and treatment of oligometastatic disease NSCLC	Cécile Le Pechoux, FR
5'	Q&A	Faculty
25'	IO or targeted therapies in the peri-operative setting for NSCLC	Jordi Remon, FR
5'	Q&A	Faculty
25'	Stereotactic ablative RT for early-stage NSCLC	Corinne Faivre-Finn, UK
5'	Q&A	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
<b>11:10-11:40</b>	<b>Coffee break</b>	
<b>11:40-13:25</b> 105'	<b>SESSION 2</b> <b>Immuno-oncology treatment paradigms</b>	<b>Chairs: Lizza Hendriks, NL</b> <b>David Planchard, FR</b>
25'	The treatment paradigm for unresectable stage III NSCLC	Fabrice Barlesi, FR
5'	Q&A	Faculty
25'	Treatment of metastatic NSCLC with PD-L1 expression and without oncogene addiction	Antonio Passaro, IT
5'	Q&A	Faculty
25'	Treatment of metastatic NSCLC with absent PD-L1 expression and without oncogene addiction	Solange Peters, CH
5'	Q&A	Faculty
15'	Participants clinical case discussion (1x15')	Faculty
<b>13:25-14:25</b>	<b>Lunch</b>	
<b>14:25-16:10</b> 105'	<b>SESSION 3</b> <b>Challenges and novel therapies in clinical oncology</b>	<b>Chairs: Keith M. Kerr, UK</b> <b>Tony S.K. Mok, HK</b>
25'	Second-line treatment for advanced NSCLC	Lizza Hendriks, NL
5'	Q&A	Faculty
25'	Prognostic and predictive biomarkers for IO	Solange Peters, CH
5'	Q&A	Faculty
25'	Antibody drug conjugates and Bi-specific Ab	David Planchard, FR
5'	Q&A	Faculty
15'	Participants clinical case discussion (1x15')	Faculty
<b>16:10-16:40</b>	<b>Coffee break</b>	

<b>16:40-18:40</b> 120'	<b>SESSION 4</b> <b>Hitting the target in 2022</b>	<b>Chairs: Benjamin Besse, FR</b> <b>Lizza Hendriks, NL</b>
25'	Sequence for biomarker testing in advanced NSCLC (IHC, PCR, NGS and more)	Keith M. Kerr, UK
5'	Q&A	Faculty
25'	New treatment options for EGFRmut NSCLC	Tony S.K. Mok, HK
5'	Q&A	Faculty
25'	The patient with an EGFR or HER2 Exon 20 insertion	Marina Garassino, US
5'	Q&A	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
<b>19:30</b>	<b>Dinner</b>	

## Friday, 18 November 2022

<b>09:00-11:00</b> 120'	<b>SESSION 5</b> <b>Hitting even more targets in 2022</b>	<b>Chairs: David Planchard, FR</b> <b>Sanjay Popat, UK</b>
25'	New treatment options for non-EGFR/HER2 mutations	Fabrice Barlesi, FR
5'	Q&A	Faculty
25'	Gene fusion targets	Benjamin Besse, FR
5'	Q&A	Faculty
25'	ctDNA in the management of NSCLC patients	Marina Garassino, US
5'	Q&A	Faculty
30'	Participants clinical case discussion (2x15')	Faculty
<b>11:00-11:30</b>	<b>Coffee break</b>	
<b>11:30-13:15</b> 105'	<b>SESSION 6</b> <b>Treatment paradigms in more rare situations</b>	<b>Chairs: Fabrice Barlesi, FR</b> <b>Marina Garassino, US</b>
25'	The evolving treatment landscape for mesothelioma	Sanjay Popat, UK
5'	Q&A	Faculty
25'	Thymic malignancies: New treatments	Benjamin Besse, FR
5'	Q&A	Faculty
25'	What's next in the management of SCLC?	David Planchard, FR
5'	Q&A	Faculty
15'	Participants clinical case discussion (1x15')	Faculty
<b>13:15-13:25</b> 10'	<b>Conclusion and farewell</b>	<b>Fabrice Barlesi, FR</b> <b>David Planchard, FR</b>
<b>13:25-14:25</b>	<b>Lunch</b>	

Note: Each 15 min slot for clinical case discussion includes 7' case presentation and 8' Q&A / interactive panel discussion